EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe
Provides Foundation For Uptake Ahead Of Upcoming EU Pharmaceutical Legislation Reform
The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.
You may also be interested in...
As the US Food and Drug Administration re-evaluates the need for comparative clinical efficacy studies for biosimilars, Leah Christl – executive director for global biosimilars regulatory affairs and R&D policy at Amgen, and former associate director for therapeutic biologics at the FDA – suggests that any reforms should be careful not to tie the agency’s hands in evaluating biosimilarity.
Draft legislation reintroduced in the US is seeking to remove the need for switching studies to demonstrate biosimilar interchangeability, making all approved biosimilars automatically interchangeable.
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.